When NSCLC cells were treated with exogenous IGF-1, an activator of PI3K/AKT pathway, the inhibition of p-AKT expression and cell proliferation was abolished in NSCLC cells with depletion of LPCAT1. This evidence concerns the gene LPCAT1 and non-small cell lung carcinoma.